A large validation study on the effect of single nucleotide polymorphisms on outcome and adverse events in sunitinib-treated patients with metastatic renal cell carcinoma (mRCC) only confirmed that ABCB1 and CYP3A5 variants are associated with progression-free survival and dose reductions, respectively. Does this mean 'game over' for polymorphism research in mRCC?
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Beuselinck, B. et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 108, 887–900 (2013).
van der Veldt, A. A. et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 17, 620–629 (2011).
Garcia-Donas, J. et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 12, 1143–1150 (2011).
Motzer, R. J. et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother. Pharmacol. 74, 739–750 (2014).
Diekstra, M. H. M. et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2015.04.018.
Xu, C. F. et al. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. Br. J. Cancer 112 (Suppl.), 1190–1198 (2015).
Beuselinck, B. et al. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol. 53, 1–10 (2014).
Mizuno, T. et al. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. Ther. Drug Monit. 36, 310–316 (2014).
Diekstra, M. H. et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin. Pharmacol. Ther. 96, 81–89 (2014).
Beuselinck, B. et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib—a multicentric retrospective analysis. Acta Oncol. 53, 103–112 (2014).
B.B. is an investigator of the EudraCT: 2011-006085-40/MetaSun trial supported by Pfizer and has received honoraria for educational activities from Amgen and GlaxoSmithKline. J.Z.-R. has received honoraria from Astellas, Bayer, Lilly and Pfizer.
Rights and permissions
About this article
Cite this article
Beuselinck, B., Zucman-Rossi, J. Single nucleotide polymorphisms in mRCC—is their time up?. Nat Rev Urol 12, 424–426 (2015). https://doi.org/10.1038/nrurol.2015.149